← Leaderboards
Federico E Rey
University Of Wisconsin-Madison
$8,049,349
Attributed
$18,288,316
Total exposure
10
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,288,316 · 10
By mechanism
R01$17,094,108 · 7
R21$744,163 · 2
R61$450,045 · 1
Top collaborators
- Barbara Brigitta Bendlin14 shared
- Tyler Kent Ulland11 shared
- Aldons Jake Lusis8 shared
- Philip Anthony Romero5 shared
- Ophelia Venturelli5 shared
- Zeneng Wang4 shared
- Kazuyuki Kasahara2 shared
- Vikas Singh2 shared
Most similar at University Of Wisconsin-Madison
Same institution · by research overlap
- Luigi Puglielli$13,206,203
- Robert F Kalejta$11,761,648
- Lloyd M Smith$20,685,320
- Rupa Sridharan$4,639,708
- Eric Robert Strieter$6,322,570
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposGut MicrobiotaGut MicrobiomeMicrobialGnotobioticLinkMouse ModelGerm-FreeMediatingMicrobiomeMicrobeGut MicrobesIntestinesAffectNovel Therapeutic InterventionPlayProductionPlasmaSamplingBacteriaCohortDesignCollectionDiet
Grant awards (34)
Ã-hydroxybutyrate inhibition of pathology in Alzheimer's disease$742,345
R01 · FY2025 · AG
Gut barrier function in Alzheimerâs disease$724,177
R01 · FY2025 · AG
Gut microbiome intervention in preclinical and clinical Alzheimer's disease$450,045
R61 · FY2025 · AG
CRCNS: Repurposing Transformers to Characterize Gut Microbiome & Aging Brain Axis$362,434
R01 · FY2025 · AG
Exploring the role of Imidazole Propionate on Alzheimerâs Disease and Related Dementias$184,385
R21 · FY2025 · AG · contact PI
Ã-hydroxybutyrate inhibition of pathology in Alzheimer's disease$752,364
R01 · FY2024 · AG
Gut barrier function in Alzheimerâs disease$740,468
R01 · FY2024 · AG
CRCNS: Repurposing Transformers to Characterize Gut Microbiome & Aging Brain Axis$369,886
R01 · FY2024 · AG
Gut barrier function in Alzheimer's Disease$249,997
R01 · FY2024 · AG
Exploring the role of Imidazole Propionate on Alzheimerâs Disease and Related Dementias$223,260
R21 · FY2024 · AG · contact PI
Ã-hydroxybutyrate inhibition of pathology in Alzheimer's disease$752,364
R01 · FY2023 · AG
Gut barrier function in Alzheimerâs disease$739,920
R01 · FY2023 · AG
Establishing mechanistic links between the gut microbiome and atherosclerosis$665,645
R01 · FY2023 · HL · contact PI
Model-guided design of next-generation bacterial therapeutics to treat cardiovascular disease$641,475
R01 · FY2023 · EB
Administrative Supplement: Model-guided design of next-generation bacterial therapeutics to treat cardiovascular disease$175,000
R01 · FY2023 · EB
Gut barrier function in Alzheimerâs disease$748,156
R01 · FY2022 · AG
Model-guided design of next-generation bacterial therapeutics to treat cardiovascular disease$661,600
R01 · FY2022 · EB
Establishing mechanistic links between the gut microbiome and atherosclerosis$654,760
R01 · FY2022 · HL · contact PI
Gut microbiota and metabolite interactions in atherosclerosis$645,180
R01 · FY2022 · HL
Gut microbiota and MAIT cell interactions in atherosclerosis$187,715
R21 · FY2022 · AG · contact PI
Gut barrier function in Alzheimerâs disease$742,527
R01 · FY2021 · AG
Model-guided design of next-generation bacterial therapeutics to treat cardiovascular disease$667,219
R01 · FY2021 · EB
Establishing mechanistic links between the gut microbiome and atherosclerosis$665,362
R01 · FY2021 · HL · contact PI
Gut microbiota and metabolite interactions in atherosclerosis$645,180
R01 · FY2021 · HL
Gut microbiota and MAIT cell interactions in atherosclerosis$148,803
R21 · FY2021 · AG
Model-guided design of next-generation bacterial therapeutics to treat cardiovascular disease$697,498
R01 · FY2020 · EB
Establishing mechanistic links between the gut microbiome and atherosclerosis$659,659
R01 · FY2020 · HL · contact PI
Gut microbiota and metabolite interactions in atherosclerosis$645,424
R01 · FY2020 · HL
Gut microbiota and metabolite interactions in atherosclerosis$673,600
R01 · FY2019 · HL
Collaborative Cross of the Microbiome and Metabolic Disease$393,488
R01 · FY2019 · DK · contact PI
Collaborative Cross of the Microbiome and Metabolic Disease$402,717
R01 · FY2018 · DK · contact PI
Collaborative Cross of the Microbiome and Metabolic Disease$409,841
R01 · FY2017 · DK · contact PI
Collaborative Cross of the Microbiome and Metabolic Disease$420,753
R01 · FY2016 · DK · contact PI
Collaborative Cross of the Microbiome and Metabolic Disease$445,069
R01 · FY2015 · DK · contact PI